Sunirudha Pharma Profile
Key Indicators
- Authorised Capital ₹ 26.00 Cr
- Paid Up Capital ₹ 25.26 Cr
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 6.59%
- Profit Growth 35.76%
- Ebitda -5.60%
- Net Worth 0.02%
- Total Assets 0.02%
About Sunirudha Pharma
Sunirudha Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 July 2017 (Seven years and six months 26 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 26.00 Cr and a paid-up capital of Rs 25.26 Cr, as per Ministry of Corporate Affairs (MCA) records.
Godrej Irani and Purushottam Adep serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304TN2017PTC121075
- Company No.
121075
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2017
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sunirudha Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Godrej Irani  | Director | 31-Jul-2017 | Current |
| Purushottam Adep | Director | 31-Jul-2017 | Current |
Financial Performance of Sunirudha Pharma.
Sunirudha Pharma Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 6.59% increase. The company also saw a substantial improvement in profitability, with a 35.76% increase in profit. The company's net worth moved up by a moderate rise of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunirudha Pharma?
In 2021, Sunirudha Pharma had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cortesia Pharma Private LimitedGodrej Irani is a mutual person
- Jivkalpa Pharma Private Limited
Godrej Irani is a mutual person
- Fortune Intercontinental Private Limited
Godrej Irani is a mutual person
- Videsh Hospitality Private Limited
Godrej Irani and Purushottam Adep are mutual person
- Naukhal Investment Private Ltd
Godrej Irani is a mutual person
- Poonawalla Art Gallery Private Limited
Godrej Irani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sunirudha Pharma?
Unlock and access historical data on people associated with Sunirudha Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunirudha Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunirudha Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.